Latest news with #PharmaceuticalTechnology
Yahoo
3 days ago
- Business
- Yahoo
‘Dupixent-fuelled' atopic dermatitis market sales to hit $22.4bn by 2033
The global atopic dermatitis (AD) market is poised to reach $22.4bn in drug sales within the decade, buoyed by the availability of targeted therapies, market analysis suggests. A 2025 report published by GlobalData, which analysed the seven major markets of the US, UK, France, Germany, Italy, Spain, and Japan, forecasts sector sales will reach the $22.4bn figure by 2033, up from $8.5bn in 2023, reflecting a compound annual growth rate (CAGR) of 10.2%. While not as fast-growing as the weight loss market in the metabolic disease space, the AD market growth is salient given the market's size compared to other dermatology indications. GlobalData healthcare analyst, Filippos Maniatis, comments: 'AD is a growing market with an impressive pipeline of new products from current and future players in the field. The AD space was previously dominated by broad-acting immunomodulatory agents, which are now being slowly replaced by more targeted agents. This shift is likely due to better comprehension of the pathophysiology behind AD and the approval of several new systemic agents.' GlobalData is the parent company of Pharmaceutical Technology. One of those targeted agents that has taken the market by storm is Regeneron and Sanofi's jointly developed Dupixent (dupilumab), first approved in the US in 2017. The blockbuster monoclonal antibody has seen its sales increase year-over-year amid high uptake from AD – reaching $14.9bn in sales in 2024. Dupixent is approved for a range of diseases, including a lucrative asthma indication. The report says that the gap of unmet need in AD, which is closing courtesy of Sanofi and Regeneron, is set to shrink even further depending on future approvals for more targeted therapies. One modality poised as a future disruptor is the OX40 inhibitor class of drugs that work by inhibiting T-cell activation and inflammation via the OX40 receptor on the immune cells. Pipeline candidates in development include Amgen and Kyowa Kirin's rocatinlimab, Sanofi's amlitelimab, and Astria Therapeutics' telazrolimab. Another class with a potential future in AD is interleukin (IL) inhibitors. LEO Pharma, GSK, and Nektar all have assets in clinical development. Maniatis concludes: 'With multiple pipeline agents in development, key unmet needs may be further addressed. Such unmet needs include the lack of personalised treatments through improved diagnostic methods, the high cost of current therapy options, the limited therapeutic options for chronic hand eczema, and better long-term disease control and management.' "'Dupixent-fuelled' atopic dermatitis market sales to hit $22.4bn by 2033" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
02-05-2025
- Business
- Yahoo
Q1 earnings pulse check: companies tentative on pharma-specific tariffs
While many pharmaceutical companies have calculated cost hits associated with US tariffs, they are reiterating that looming pharma-specific tariffs create an uncertain financial outlook for the year ahead. The first-quarter (Q1) earnings season has provided an opportunity for pharmaceutical companies to comment on the financial impact of existing tariffs and offer clues as to how future tariffs could affect 2025 performance. A common theme among Q1 earnings reports was a 2025 guidance that included the impact of current tariffs whilst excluding any future effects from pharmaceutical sector-specific ones. That instead left executives commenting on the nature of future impacts, as opposed to a material figure. For those who have released Q1 results, many are already performing above estimates, with executives expressing confidence in their company's ability to navigate the much-changed trade economy. Pharmaceutical Technology analysed select Q1 earnings reports and equity research notes from William Blair. Modelling has become as critical as ever for companies this year. BioMarin Pharmaceutical, for example, said that whilst its current guidance does not reflect future pharmaceutical tariffs, it is modelling all scenarios and evaluating potential mitigating tactics. Moderna stated it would incur minimal impact from potential tariffs, with the US big pharma's drug substance currently produced in the 200,000ft² manufacturing facility in Massachusetts. The company also expects new overseas production facilities to be operational this year, helping regional supplies of its products. UK-headquartered GSK, meanwhile, said it remains confident in its ability to absorb the impacts of potential pharmaceutical tariffs in the US by increasing operational efficiency, supply chain resilience and further expansion of its US manufacturing footprint. Expanding production to US manufacturing has been the name of the game for many pharma companies. Roche, for example, outlaid $50bn (SFr41.22bn) in investments for pharmaceuticals and diagnostics in the US over the next five years to counter Trump's tariffs. Johnson & Johnson (J&J), which announced its own $55m US manufacturing investment in March 2025, was one of several companies to place a number on tariff costs. It expects a $400m hit tied to existing and newly proposed tariffs, although most of this burden will fall on its medtech division. Pfizer expects a lower hit than J&J, forecasting costs of around $150m due to existing tariffs this year. Whilst other companies have been quick to double down in the US manufacturing space, CEO Albert Bourla said that uncertainty around Trump's planned pharmaceutical tariffs is deterring further investment in the country. MSD's CEO Rob Davis pointed to $200m in added costs for existing tariffs, mostly via China. The company plans to spend $9bn on US manufacturing and research and development. Regardless of how pharma companies' financials look after further tariffs are implemented, effects are still likely to be felt by patients. Analysis by GlobalData indicates that pharmaceutical tariffs could create a pivotal moment in the industry that may reshape consumer access to medicine. How companies deal with tariffs will be a key factor in dictating the prices and availability of drugs in the US in 2025. GlobalData is the parent company of Pharmaceutical Technology. Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence "Q1 earnings pulse check: companies tentative on pharma-specific tariffs" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
30-04-2025
- Business
- Yahoo
US tariffs likely to disrupt drug development costs and prices, says GlobalData
While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the pharmaceutical supply chain. With US President Donald Trump leaning towards implementing additional tariffs on the pharmaceutical sector, there is potential to disrupt drug development costs and drug prices, with any tariffs increasing the import costs of many raw materials and active pharmaceutical ingredients, according to GlobalData, a leading data and analytics company. According to GlobalData's 2025 report, China is currently the world's second-largest single country market, following the US, with pharmaceutical market sales expected to hit 2trn yuan ($273.9bn) in 2025. On 4 April 2025, Trump imposed an additional 34% tariff on all Chinese imports, with China responding with a reciprocal 34% tariff on all goods imported from the US. The Chinese government has also subjected an additional 16 US organisations and companies to trade sanctions or export controls, as well as adding 11 companies to the unreliable entity list on 5 April 2025, limiting investment activities in China. The volatile relations between the US and China are expected to significantly affect the international pharmaceutical market, with any future-imposed pharmaceutical tariffs potentially resulting in increased costs of drugs, limited patient availability, and logistical difficulties, with several organisations considering relocation to tackle this issue. On 9 April 2025, China's Ministry of Finance announced an 84% retaliatory tariff on all goods imported from the US to take place from 10 April 2025, up from 34%, in response to Trump's recent levy hikes. This follows the US' imposition of a 125% tariff on Chinese imports on 9 April 2025, up from 104%, accelerating the trade war between the two nations. Due to the current lack of exemptions for the pharmaceutical industry by the Chinese government, imported pharmaceutical products and vaccines will be subjected to the additional tariffs. Trump has also stated that the imposed tariffs on the pharmaceutical industry will cause organisations to reshore their manufacturing to the US, with no specific timeline on when the pharmaceutical tariffs are to be imposed. "US tariffs likely to disrupt drug development costs and prices, says GlobalData" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
28-04-2025
- Business
- Yahoo
Amgen to invest $900m in Ohio manufacturing facility
Amgen has announced a significant expansion of a manufacturing facility in the US state of Ohio, with an investment of $900m. The move brings the total investment in Central Ohio to more than $1.4bn, and the total number of national employment opportunities created to 750. The expansion is part of the company's strategy to enhance its manufacturing offerings in the US. It first established its presence in the Ohio region in June 2021 with the announcement of a biomanufacturing facility in the Columbus Region, generating 400 employment opportunities. In February 2024, the company opened the 300,000 ft² Ohio facility to meet the growing demand for its medications within the country. Following the Tax Cuts and Jobs Act of 2017, Amgen has made substantial investments in the US. It has invested almost $5bn in direct capital expenditures, contributing an additional $12bn in downstream output to the country's economy. The Ohio expansion is part of Amgen's worldwide biomanufacturing network, which benefits from operational expertise and technological advancements. The investments across the US align with the company's focus on establishing biologics manufacturing capabilities globally. Amgen CEO and chairman Robert Bradway stated: "Today's investment reinforces our ongoing commitment to expanding US manufacturing and ensuring patients around the world have access to our innovative medicines. "Ohio offers a supportive business climate, skilled workforce and strategic location, making it an ideal choice for this next phase of our investment." In January 2025, Amgen inaugurated a new drug substance facility in the US after announcing a further $1bn expansion at its North Carolina site. "Amgen to invest $900m in Ohio manufacturing facility" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
24-04-2025
- Business
- Yahoo
Thermo Fisher counters tariffs with $2bn investment into US manufacturing
Thermo Fisher has outlaid $2bn to expand manufacturing and development in the US, joining the long list of companies directing resources to domestic operations as ongoing US tariffs risk destabilising global trade. The life sciences giant, which provides products and services to biopharma companies manufacturing drugs, said the $2bn will be invested over the next four years. Thermo Fisher said $1.5bn in capital expenditure would go towards enhancing and expanding US manufacturing operations, whilst the remaining $500m would be directed towards research & development (R&D). There are 64 manufacturing sites operated by Thermo Fisher in the US that provide contract development and manufacturing services for pharmaceutical innovators. Facilities also make analytical instruments, specialty diagnostics and other solutions in the life sciences space. Thermo Fisher did not immediately respond to Pharmaceutical Technology on whether existing sites would benefit from the investment or whether new facilities would be developed over the coming years. Efforts to shore up US manufacturing capabilities come at a time when tariffs announced by US President Donald Trump have made importing into the country less attractive. The government has also threatened tariffs on pharmaceutical imports, an area that previously escaped the blanket levies. The $2bn is a commitment by Thermo Fisher to US manufacturing amid the volatile international trade channels. '[It] reflects our confidence that America will continue to lead the world in science and innovation,' Thermo Fisher's CEO Marc Casper said. 'By expanding our US operations, we ensure that life-saving medicines and therapies will continue to be developed and produced in America for decades to come,' he added. The US expansion is set to counteract headwinds in business operations reported in its Q1 earnings, on 23 April. Thermo Fisher estimates a $400m hit to its sales of products in China this year. Revenue in the country accounts for around 8% of its business. Wall Street was unmoved despite the shaky outlook, with shares in the NYSE-listed company being down by only 0.4% when the markets opened on 24 April following the Q1 earnings report on the previous day. Investor caution was potentially tempered by the $2bn earmarked for US operations. In a Q1 earnings call, chief financial officer Stephen Williamson said sales of the company's US-manufactured products in China would be affected by the ongoing trade disputes. Likewise, the cost of parts manufactured in China, which Thermo Fisher relies on for assembly, would be affected by tariffs. Intuitive Surgical, developer surgical robotic systems, revealed similar impacts in its Q1 report. Thermo Fisher is one of many companies redirecting resources to the US in an effort to make supply chains more robust. Earlier this week, Roche unveiled a $50bn investment strategy to upgrade three R&D sites in the US. Novartis, Johnson & Johnson and Eli Lilly have also made similar investment announcements. The current investment by Thermo Fisher follows $4.1bn spent by the company in February 2025 to acquire Solventum's purification & filtration business unit that has a global footprint, including sites in North America. Not all of Thermo Fisher's US sites have enjoyed investment recently. The company continued its strategic withdrawal from the viral vector manufacturing space in February, cutting headcount at two of its US facilities by 300. Weaker demand for drug manufacturing in recent years has led to several other cost-cutting initiatives, including redundancies at its plasmid manufacturing site in California, the closure of its biologics development and cell therapy services facility in New Jersey, and gene therapy facilities in Florida. Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence here. "Thermo Fisher counters tariffs with $2bn investment into US manufacturing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
